Page Title
We live product development – transforming ground-breaking ideas into life-saving medication.

News

Prime update: visit to the East African clinical sites

We are pleased that after the long COVID lockdown we were also able to visit the East African sites to touch base and to discuss the conduct of the trial and potential improvements. We thank all centres for their warm welcome and their hospitality during our stay and hope to meet more often in person again.

Results of SAKK 06/14 trial with VPM1002BC as treatment for non-muscle-invasive bladder cancer have been published in European Urology Oncology

The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions. Please click here to read the publication.

priMe update: visit of the South African clinical sites

We are pleased that after the long COVID lockdown we were able to visit the south African sites to touch base and to discuss the conduct of the trial and potential improvements. We thanks all centres for their warm welcome and their hospitality during our stay and hope that, once everything is more or less back to normal, we’ll meet more often in person again.

Scroll to Top